<PAGE> 1
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES
EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)
Filed by the Registrant [X]
Filed by a Party other than the Registrant [ ]
Check the appropriate box:
<TABLE>
<S> <C>
[ ]Preliminary Proxy Statement [ ] Confidential, for Use of the
[ ]Definitive Proxy Statement Commission Only (as permitted
[X]Definitive Additional Materials by Rule 14a-6(e)(2))
[ ]Soliciting Material Pursuant to sec.
240.14a-11(c) or sec. 240.14a-12
</TABLE>
ICN PHARMACEUTICALS, INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the
Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] Fee not required.
[ ] Fee computed on table below per Exchange Act Rules 14a-
6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transaction applies:
(3) Per unit price or other underlying value of transaction
computed pursuant to Exchange Act Rule 0-11 (Set forth the
amount on which the filing fee is calculated and state how
it was determined):
(4) Proposed maximum aggregate value of transaction:
(5) Total fee paid:
[ ] Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided
by Exchange Act Rule 0-11(a)(2) and identify the filing for
which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the Form
or Schedule and the date of its filing.
(1) Amount Previously Paid:
(2) Form, Schedule or Registration Statement No.:
(3) Filing Party:
(4) Date Filed:
<PAGE> 2
SCHERING-PLOUGH AND ICN PHARMACEUTICALS
ANNOUNCE STRATEGIC LICENSING AGREEMENT
KENILWORTH, N.J., and COSTA MESA, Calif., Nov. 15, 2000 -
Schering-Plough Corporation (NYSE: SGP) and ICN Pharmaceuticals,
Inc. (NYSE: ICN) today announced a long-term strategic agreement
for the licensing of drugs for the treatment of hepatitis C and
other indications.
Under terms of the agreement, Schering-Plough has the right
of first and last refusal to license two antiviral drugs
currently in the ICN research pipeline, levovirin and viramidine,
and other compounds that ICN may develop in infectious and other
diseases, as well as the exclusive option for an exclusive
worldwide license for up to three hepatitis C drugs to be
developed by ICN.
"ICN and Schering-Plough have an excellent and mutually
rewarding business relationship that will now continue well into
the future," said Milan Panic, chairman and CEO of ICN. "We look
forward to continuing our already successful relationship in the
battle against hepatitis C and other diseases," Panic said.
"We are pleased to enter into this new agreement, which
continues our successful relationship with ICN and provides the
opportunity to expand and complement Schering-Plough's ongoing
research efforts in hepatitis and other infectious diseases,"
said Thomas C. Lauda, executive vice president, global marketing,
Schering-Plough Pharmaceuticals.
Royalty rates and other financial terms of the agreement
were not disclosed.
It is estimated that about 2 percent of the world population
is currently infected with the hepatitis C virus. This includes
some 4 million Americans, according to the Centers for Disease
Control and Prevention (CDC), and as many as 5 million Europeans,
according to a study conducted by the World Health Organization
(WHO). Chronic hepatitis C is the leading cause of chronic liver
disease and the most common reason for liver transplants,
according to WHO.
The new agreement also resolves claims by Schering-Plough
related to the hiring of former Schering-Plough scientists by ICN
and the existing licensing agreement between the two companies.
ICN is an innovative, research-based global pharmaceutical
company that manufactures, markets and distributes a broad range
of prescription and non-prescription pharmaceuticals under the
ICN brand name. Its therapeutic focus is on anti-infectives,
including antivirals, dermatology and oncology. Additional
information is also available on the company's Web site at
http://www.icnpharm.com
Schering-Plough Pharmaceuticals is the worldwide
pharmaceutical research and marketing arm of Schering-Plough
Corporation, a research-based company engaged in the discovery,
development, manufacturing and marketing of pharmaceutical
products worldwide.
